Business Wire

EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally

Share

Boomi™, the intelligent connectivity and automation leader, today announced that leading UK-based technology distributor EXERTIS is expanding its use of Boomi’s category-leading, unified integration platform to improve partner and customer satisfaction on a global scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808691045/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally (Graphic: Business Wire)

EXERTIS works with 2,400 technology partners, including Apple, Samsung, Microsoft, and Dell Technologies, and serves more than 50,000 retailers and resellers in 20+ countries. As part of a full spectrum of services, EXERTIS supplies IT hardware and software to electronic retailers and hosts some clients’ ecommerce stores, managing their full, end-to-end customer journeys.

Prior to using Boomi, EXERTIS had grown through acquisition, where each of its operating entities possessed a mix of legacy and modern integration tools. As a result, manual custom coding; ageing, on-premises enterprise service bus (ESB) systems; and outdated electronic data interchange (EDI) tools and services were widespread and disconnected. This led to slow development and deployment of new integrations, high technical debt, and a declining pool of developers with specialised skills that stifled the scalability and flexibility EXERTIS needed.

With an acquisition strategy that benefitted from inter-company trade synergies, EXERTIS needed a future-proof solution. After evaluating various integration and EDI solutions, EXERTIS saw how Boomi could modernise its IT environment and support its growth and acquisition strategy through the platform’s low-code ease of use; speed of development; and multiple capabilities in a unified, multi-tenant, cloud-based solution.

Using its core integration, B2B/EDI management, and API management capabilities, the Boomi platform enables EXERTIS to connect into over 100 internal and third-party systems with 200 more systems in the pipeline, providing EXERTIS with the agility for further innovation.

“EXERTIS has its origins in venture capitalism and private equity, and a core part of our work centred around the integration of acquired entities,” said Tim Griffin, CEO, EXERTIS. “There are lots of solutions on the market, but I would put Boomi at the top, especially when you consider its multi-tenant architecture and cloud basis. Our developers became proficient in as little as three weeks, and we now have a shared development environment that promotes reuse of integrations across our business.”

In light of its early success, EXERTIS is expanding its use of Boomi to digitally transform its global environment for integration and EDI transactions, and improve partner and customer satisfaction on a global scale.

“We’re delighted to expand our engagement and support of EXERTIS as they continue to grow globally,” said Adrian Trickett, Vice President and General Manager, EMEA at Boomi. “By enabling frictionless transactions, EXERTIS has increased the percentage of orders from its partners and customers, and freed time for its people to pursue more value-adding work.”

Learn more about the EXERTIS use case with Boomi here.

Additional Resources

About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organisations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.

© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye